Finally, given the role of NFκB in enhancing sunitinib resistance [29, 30], we found that downregulation of SEC14L3 enhances the sensitivity of ccRCC cells to sunitinib treatment. The gene discussed is SEC14L3; the disease is nonpapillary renal cell carcinoma.